NVO: 6-K company filing

6-K 1 f6k_101226.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 12, 2026 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé 1 DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☒ Form 40-F ☐ Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 12 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027. Since the announcement 5 October, the following transactions have been made: Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement 21,845,000 6,447,270,879 5 October 2026 245,000 246.39 60,365,707 6 October 2026 250,000 247.50 61,874,647 7 October 2026 250,000 250.87 62,717,325 8 October 2026 250,000 251.66 62,914,296 9 October 2026 250,000 254.93 63,733,579 Accumulated under the programme 23,090,000 6,758,876,433 The details for each tra